Position Papers

• 2007 - ''Generic Drug Pricing in Canada'', author: Ward Health Strategies

• 2006 - ''Timeliness and Transparency : Accessing the Review Process for HIV Drugs'' - REVISED APRIL 2006- author: David Garmaise.

• 2004 - “Roadmap for Addressing the Epidemic of HIV and Hepatitis C Co-Infection in Canada”, author: Paula Braitstein.
  • Appendix 1
  • Appendix 2
  • Appendix 3
    

     

• 2001 - “Improving our Health: The Need to Enhance the Post-Approval Surveillance System for HIV/AIDS Drugs in Canada”, author: David Garmaise.

   

  • Appendix A: Organization Charts
  • Appendix B: Form: Report of adverse reaction suspected due to
    drugs, cosmetics and biological products (Vaccines excluded)
  • Appendix C: Canadian Adverse Drug Reaction Newsletter (Sample Issue)
  • Appendix D: Recommendations of the Consultative Working Group on the Therapeutic Products Programme Drug Review Process
    

• 2001 - “Making
  Treatments Accessible: A Policy Paper on Determining Appropriate
  Pricing for Brand-name Pharmaceutical Treatments for HIV/AIDS in Canada”, author:Glen Brown.

• 2000 - “Position Paper on Direct to Consumer Advertising (DTCA) of Prescription Medications”, author: Philip Lundrigan.

Permission is given to reproduce all or any part of the papers provided appropriate accreditation is given.